These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14741168)

  • 1. Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.
    Davis D; Donners H; Willems B; Lövgren-Bengtsson K; Akerblom L; Vanham G; Barnett S; Morein B; Heeney JL; van der Groen G
    Vaccine; 2004 Jan; 22(5-6):747-54. PubMed ID: 14741168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.
    Donners H; Vermoesen T; Willems B; Davis D; van der Groen G
    Vaccine; 2003 Dec; 22(1):104-11. PubMed ID: 14604577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen.
    Davis D; Morein B; Akerblom L; Lövgren-Bengtsson K; van Gils ME; Bogers WM; Teeuwsen VJ; Heeney JL
    Vaccine; 1997 Oct; 15(15):1661-9. PubMed ID: 9364697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.
    Hart MK; Palker TJ; Matthews TJ; Langlois AJ; Lerche NW; Martin ME; Scearce RM; McDanal C; Bolognesi DP; Haynes BF
    J Immunol; 1990 Oct; 145(8):2677-85. PubMed ID: 1698859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
    Haigwood NL; Nara PL; Brooks E; Van Nest GA; Ott G; Higgins KW; Dunlop N; Scandella CJ; Eichberg JW; Steimer KS
    J Virol; 1992 Jan; 66(1):172-82. PubMed ID: 1727480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
    Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
    J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
    Berman PW; Murthy KK; Wrin T; Vennari JC; Cobb EK; Eastman DJ; Champe M; Nakamura GR; Davison D; Powell MF; Bussiere J; Francis DP; Matthews T; Gregory TJ; Obijeski JF
    J Infect Dis; 1996 Jan; 173(1):52-9. PubMed ID: 8537682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunogenicity of recombinant adeno-asscociated virus type 1 expressing HIV-1 gp120 gene in mice and Rhesus macaques].
    Yu SQ; Feng X; Liu HM; Yang HR; Li HX; Zeng Y
    Bing Du Xue Bao; 2010 Mar; 26(2):115-20. PubMed ID: 20480640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: a later variant isolated from the same host.
    Davis D; Trischmann H; Stephens DM; Lachmann PJ
    J Med Virol; 2001 Jul; 64(3):207-16. PubMed ID: 11424106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
    Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
    AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.